Tag: Novartis

September 29, 2021 Off

Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life

By Dino Mustafić

Novartis’ dana from new analysis from a Phase IIb study has showed the importance of achieving complete control of chronic spontaneous urticaria (CSU) symptoms in improving overall health-related quality of life (HRQoL) for patients, as complete control of symptoms brings enormous benefit to people with CSU and is associated with improvements in key HRQoL measures such as overall quality of life, sleep interference, activity interference and work impairment.

September 13, 2021 Off

USFDA accepts Novartis’ tislelizumab for people with esophageal cancer

By Dino Mustafić

Novartis got an acceptance by the US Food and Drug Administration (FDA) for its Biologics License Application (BLA) for anti-PD-1 immune checkpoint inhibitor tislelizumab for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in people who had received prior systemic therapy.